BNTX Novinky na Forexe
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants
The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews
|
Pred 125 dňami
Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine
Drug giant Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.
RTTNews
|
Pred 131 dňami
BioNTech And CEPI Expand Strategic Partnership To Boost African Vaccine Ecosystem
BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations or CEPI, announced Wednesday they are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.
RTTNews
|
Pred 210 dňami
BioNTech Slips To Loss In Q1
Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.
RTTNews
|
Pred 233 dňami
BioNTech Q4 Net Profit Plummets
Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) announced Wednesday a profit for the fourth quarter that plummeted from last year, reflecting sharply lower global delivery of its COVID-19 vaccine. The company also initiated its group revenue guidance for the full-year 2024.
RTTNews
|
Pred 280 dňami
BioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166
BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox)
RTTNews
|
Pred 464 dňami
FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines
The U.S. Food and Drug Administration said it has amended the emergency use authorizations or EUAs of COVID-19 bivalent mRNA vaccines of ModernaTX Inc. and Pfizer-BioNTech to simplify the vaccination schedule for most individuals. With the changes, the current bivalent vaccines, for original and omicron BA.4/BA.5 strains, can be used for all doses administered to individuals 6 months of age and...
RTTNews
|
Pred 617 dňami
FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5
The U.S. Food and Drug Administration has authorized bivalent Pfizer-BioNTech covid-19 vaccine as booster dose for certain children 6 months through 4 years of age. In a statement, the health regulator said it has amended the emergency use authorization or EUA of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. According to the agency, children 6 months through 4 years of age who completed ...
RTTNews
|
Pred 652 dňami
Pfizer Seeks FDA Approval For Bivalent COVID-19 Vaccine In Kids Under 5
Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
RTTNews
|
Pred 750 dňami
BioNTech Q3 Profit Down; Lifts FY22 COVID-19 Vaccine Revenue View
German biotechnology company BioNTech SE reported Monday sharply lower profit in its third quarter reflecting weak revenues. Looking ahead, BioNTech has raised the lower end of its fiscal 2022 COVID-19 vaccine revenue estimate. In pre-market activity in Nasdaq, BioNTech shares were losing around 3.2 percent.
RTTNews
|
Pred 779 dňami
